Author

Y.-M. Zheng

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 10 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 11 Approach:experimental assay· 10 Organism:human· 8 Assay:proteomics· 5 Research Focus:drug response / drug discovery· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:protein folding & dynamics· 1 Assay:protein structure· 1

Frequent Co-Authors

S.-L. Liu· 11 shared E. M. Oltz· 10 shared C. Carlin· 9 shared L. J. Saif· 9 shared P. Qu· 9 shared R. J. Gumina· 9 shared J. P. Evans· 8 shared K. Xu· 7 shared

Activity by Year

2021-2024 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

11 shared papersMicrobiology

S.-L. Liu

Mutual co-authors in cluster

Author profile →

11 papers

Recent·Most cited

Distinct Patterns of SARS-CoV-2 BA.2.87.1 and JN.1 Variants in Immune Evasion, Antigenicity and Cell-Cell Fusion

P. Li, Y. Liu, J. Faraone, C. C. Hsu, M. Chamblee, Y.-M. Zheng, C. Carlin, J. S. Bednash, J. C. Horowitz, R. K. Mallampalli, L. J. Saif, E. M. Oltz, D. Jones, J. Li, R. J. Gumina, S.-L. Liu

This study compares immune evasion, antigenicity, and cell-cell fusion properties of SARS-CoV-2 BA.2.87.1 and JN.1 variants, finding BA.2.87.1 shows less neutralization escape and higher infectivity than JN.1 and XBB.1.5.

bioRxiv · Mar 11, 2024Microbiology

Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants

P. Qu, K. Xu, J. N. Faraone, N. Goodarzi, Y.-M. Zheng, C. Carlin, J. S. Bednash, J. C. Horowitz, R. K. Mallampalli, L. J. Saif, E. M. Oltz, D. Jones, R. J. Gumina, S.-L. Liu

This study compares immune evasion, infectivity, and fusogenicity of SARS-CoV-2 variants BA.2.86 and FLip using neutralization assays and cell-based experiments.

bioRxiv · Sep 11, 2023Microbiology

Immune Evasion and Membrane Fusion of SARS-CoV-2 XBB Subvariants EG.5.1 and XBB.2.3

J. N. Faraone, P. Qu, N. Goodarzi, Y.-M. Zheng, C. Carlin, L. J. Saif, E. M. Oltz, K. Xu, D. Jones, R. J. Gumina, S.-L. Liu

This study evaluates neutralization and fusion activity of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3, showing reduced neutralization by bivalent vaccines and highlighting the need for updated vaccine formulations.

bioRxiv · Aug 30, 2023Immunology

Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants

P. Qu, J. N. Faraone, J. P. Evans, Y.-M. Zheng, C. Carlin, M. Anghelina, P. Stevens, S. Fernandez, D. Jones, G. Lozanski, A. Panchal, L. J. Saif, E. M. Oltz, K. Xu, R. J. Gumina, S.-L. Liu

This study evaluates neutralizing antibody escape by Omicron subvariants XBB.1.5, CH.1.1, and CA.3.1, showing near-complete escape from mRNA vaccines but partial rescue with bivalent boosters.

bioRxiv · Jan 16, 2023 · PreprintMicrobiology

Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2

P. Qu, J. P. Evans, J. Faraone, Y.-M. Zheng, C. Carlin, M. Anghelina, P. Stevens, S. Fernandez, D. Jones, G. Lozanski, A. Panchal, L. J. Saif, E. M. Oltz, K. Xu, R. J. Gumina, S.-L. Liu

This study evaluates neutralization resistance and immune evasion mechanisms of SARS-CoV-2 Omicron subvariants against various sera, identifying key mutations driving resistance.

bioRxiv · Oct 19, 2022 · PreprintMicrobiology

Determinants and Mechanisms of the Low Fusogenicity and Endosomal Entry of Omicron Subvariants

P. Qu, J. P. Evans, C. Kurhade, C. Zeng, Y.-M. Zheng, K. Xu, P.-Y. Shi, X. Xie, S.-L. Liu

This study identifies mutations in the Omicron subvariant spike protein that reduce fusogenicity and increase endosomal entry, revealing mechanisms behind their immune evasion and pathogenesis.

bioRxiv · Oct 15, 2022 · PreprintMicrobiology

Evasion of Neutralizing Antibody Response by the SARS-CoV-2 BA.2.75 Variant

P. Qu, J. P. Evans, Y.-M. Zheng, C. Carlin, L. J. Saif, E. M. Oltz, K. Xu, R. J. Gumina, S.-L. Liu

This study investigates how the BA.2.75 SARS-CoV-2 variant evades neutralizing antibodies through specific mutations and shows enhanced cell-cell fusion.

bioRxiv · Aug 14, 2022Microbiology

Durability of the Neutralizing Antibody Response to mRNA Booster Vaccination Against SARS-CoV-2 BA.2.12.1 and BA.4/5 Variants

P. QU, J. N. Faraone, J. P. Evans, Y.-M. Zheng, C. Carlin, G. Lozanski, L. J. Saif, E. M. Oltz, R. J. Gumina, S.-L. Liu

This study examines the durability of neutralizing antibody responses to SARS-CoV-2 BA.2.12.1 and BA.4/5 variants after mRNA booster vaccination, finding significant waning but stable responses compared to two-dose immunity.

bioRxiv · Jul 21, 2022 · PreprintMicrobiology

Differential Evasion of Delta and Omicron Immunity and Enhanced Fusogenicity of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants

P. Qu, J. P. Evans, J. N. Faraone, X. Zou, Y.-M. Zheng, C. Carlin, J. S. Bednash, G. Lozanski, R. K. Mallampalli, L. J. Saif, E. M. Oltz, P. J. Mohler, R. J. Gumina, S.-L. Liu

This study compares the neutralization resistance, infectivity, and fusogenicity of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 subvariants to other variants and finds increased resistance and fusogenicity linked to L452 mutations.

bioRxiv · May 16, 2022 · PreprintMicrobiology

Neutralization and Stability of SARS-CoV-2 Omicron Variant

Z. Cong, J. P. Evans, P. Qu, J. Faraone, Y.-M. Zheng, C. Carlin, J. S. Bednash, T. Zhou, G. Lozanski, R. Mallampalli, L. J. Saif, E. M. Oltz, P. Mohler, K. Xu, R. J. Gumina, S.-L. Liu

This study investigates the immune evasion and transmissibility of the SARS-CoV-2 Omicron variant, showing significant immune evasion but restored neutralization with booster doses and increased transmissibility due to a more stable spike protein structure.

bioRxiv · Dec 16, 2021 · PreprintMicrobiology

SARS-CoV-2 Spreads through Cell-to-Cell Transmission

C. Zeng, J. P. Evans, T. King, Y.-M. Zheng, E. M. Oltz, S. P. J. Whelan, L. Saif, M. E. Peeples, S.-L. Liu

This study shows SARS-CoV-2 spreads through cell-to-cell contact via spike glycoprotein, which is more efficient than SARS-CoV and resistant to neutralizing antibodies.

bioRxiv · Jun 1, 2021Microbiology